Early Phase II data from the PISCES II study of UK-based stem cell company ReNeuron’s CTX cell therapy candidate have further reinforced its promise as a treatment for stroke disability, a large unmet medical need.
Although the data from the single-arm open-label study in patients living with disability resulting from ischaemic stroke did not quite...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?